TOKYO--(BUSINESS WIRE)--Oct 9, 2026--
Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolina, today announced that the U.S. Food and Drug Administration (FDA) has approved HOVILPRI ® (pritelivir) 100 mg tablets for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacyclovir, or famciclovir in immunocompromised adults. HOVILPRI, a novel helicase-primase inhibitor, was developed by AiCuris Anti-infective Cures AG, which is now a part of Asahi Kasei Therapeutics. 1,2
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009917279/en/
“Today's approval delivers the first FDA-approved treatment for refractory mucocutaneous HSV lesions with a novel mechanism of action in nearly 30 years and marks an important advancement for immunocompromised adults,” said Stacy Wheeler, Chief Executive Officer of Asahi Kasei Therapeutics in the U.S. and Europe. “HOVILPRI offers a new oral treatment option for adult patients with a persistent, difficult-to-treat disease.” 1,3,7-10
In immunocompetent adults, HSV infection is often asymptomatic or associated with mild disease. In immunocompromised adults, including hematopoietic stem cell and solid organ transplant recipients, people living with HIV, and patients with malignancies or autoimmune and inflammatory conditions, HSV infection can occur more frequently and may be more severe. Refractory HSV infection can result in prolonged and difficult-to-treat mucocutaneous disease. 7-10 Because nucleoside analogue therapies such as acyclovir require activation by the viral thymidine kinase (TK) enzyme, mutations in TK can reduce susceptibility to these treatments in some patients. 2,9 When HSV infection does not improve with nucleoside analogue therapy, available treatment options have often required intravenous administration and may present additional treatment-management challenges for patients and healthcare teams. 8-10 HOVILPRI is a helicase-primase inhibitor with a mechanism of action distinct from nucleoside analogue therapies. 1,2
The approval is supported by results from PRIOH-1 Part C, the pivotal Phase 3 randomized, open-label, comparator-controlled superiority trial in immunocompromised adults with mucocutaneous HSV infection that was refractory, with or without documented resistance, to acyclovir, valacyclovir, or famciclovir. The trial met its primary efficacy endpoint, demonstrating superiority of HOVILPRI over Investigator's Choice treatment, after up to 28 days of treatment. By Day 28, HOVILPRI achieved a significantly higher rate of complete lesion healing vs Investigator's Choice (63% vs 34% respectively, corresponding to an adjusted treatment difference of 28.4% (95% CI: 9.6, 47.3; p=0.0047). Up to day 42, the observed response rates were 82% for HOVILPRI and 42% for Investigator's Choice treatment, corresponding to an adjusted treatment difference of 40.0% (95% CI: 22.7, 57.7). 1,4
In Part C of the pivotal Phase 3 PRIOH-1 trial, adverse reactions were reported less frequently in participants treated with HOVILPRI compared with Investigator's Choice treatment (22% vs. 54%). Discontinuations due to adverse drug reactions were also less frequent with HOVILPRI compared with Investigator's Choice treatment (2% vs. 20%). The most common adverse reaction was headache, occurring in 6% of patients taking HOVILPRI and 4% of patients taking Investigators Choice. 1
“In patients with blood cancers or those who have undergone stem cell transplantation, refractory HSV infections can be prolonged, painful, and difficult to treat, while available intravenous treatments carry substantial risks,” said Genovefa Papanicolaou, MD, Clinical Director of Infectious Disease Service at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell College of Medicine, and a PRIOH-1 investigator. “In PRIOH-1, pritelivir demonstrated superior lesion healing compared with Investigator’s Choice treatment up to day 28.” 1,4,7-10
“Refractory HSV can be a serious clinical challenge for immunocompromised adults, a population with limited treatment options,” said Carl Kraus, Chief Medical Officer at Asahi Kasei Therapeutics. “The approval of HOVILPRI reflects years of clinical research in refractory HSV and reinforces our commitment to advancing scientifically differentiated medicines for patients whose conditions remain difficult to treat. We are grateful to the patients, investigators, clinical teams, and scientific community whose contributions made this milestone possible.” 1,4,7-10
HOVILPRI is expected to be available in the United States before the end of 2026. U.S. Healthcare providers can learn more about HOVILPRI at www.hovilprihcp.com.
About the PRIOH-1 Trial
PRIOH-1 (NCT03073967 / Eudra-CT 2023-510088-37-00) is a global, controlled, open-label, comparative trial evaluating pritelivir in immunocompromised adults with refractory or resistant HSV infection. The registrational Phase 3 portion (Part C) randomized and treated 101 immunocompromised adults with mucocutaneous HSV infection that was refractory with or without documented resistance to acyclovir, valacyclovir, or famciclovir. This included hematopoietic cell and solid organ transplant recipients, patients with malignancies, autoimmune or inflammatory disorders, and people living with HIV. Participants received either oral pritelivir (400 mg loading dose on Day 1 followed by 100 mg once daily) or Investigator's Choice treatment (IV foscarnet, IV/topical cidofovir, or 5% topical imiquimod) for up to 28 days, with treatment extended to 42 days if lesions were improving. Pritelivir met its primary endpoint demonstrating statistically significant superiority in lesion healing up to Day 28 compared with Investigator’s Choice treatment. 1,4
About Herpes Simplex Virus
Herpes Simplex Virus (HSV) includes two types, HSV-1 and HSV-2, both of which cause lifelong infections; there is no cure. HSV-1 most commonly causes labial herpes, while HSV-2 is the primary cause of genital herpes. Although many people with HSV infection never develop symptoms, the virus can reactivate to cause recurrent, painful lesions and may cause complications in certain cases. 11-12 HSV represents a substantial global public health burden: an estimated 3.8 billion people under the age of 50 (64% of the global population) were infected with HSV-1 in 2020, and approximately 520 million people aged 15 to 49 were living with HSV-2. 11 The disease burden is particularly high in immunocompromised patients, whose weakened immune systems leave them at increased risk of more frequent, more severe, and treatment-refractory HSV infections. 7,9-10
About HOVILPRI (pritelivir)
HOVILPRI is an orally administered HSV helicase-primase inhibitor indicated for the treatment of mucocutaneous lesions caused by HSV infection that is refractory, with or without documented resistance, to acyclovir, valacyclovir, or famciclovir in immunocompromised adults. HOVILPRI is active against both HSV-1 and HSV-2, including strains resistant to nucleoside analogs and foscarnet. In the pivotal Phase 3 PRIOH-1 trial, HOVILPRI demonstrated statistically significant superiority in lesion healing up to day 28 compared to Investigator's Choice treatment. The most common adverse reaction reported with HOVILPRI was headache. 1-2,4
INDICATION AND IMPORTANT SAFETY INFORMATION FOR US AUDIENCE
Indication
HOVILPRI (pritelivir) tablets is indicated in immunocompromised adults for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacyclovir, or famciclovir.
Important Safety Information
Warnings and Precautions
Drug Interactions With Acid-reducing Agents: Concomitant use of HOVILPRI with certain acid-reducing agents may reduce pritelivir exposure, potentially resulting in reduced therapeutic effect and development of resistance. Avoid concomitant use with certain proton pump inhibitors, and stagger concomitant use with H2-receptor antagonists and antacids.
Adverse Reactions: In clinical studies, the adverse reaction (all grades) occurring in more than 5% of participants receiving HOVILPRI was headache, which occurred in 6% and 4% of the HOVILPRI and Investigator’s Choice participants, respectively.
Drug Interactions:
Pritelivir is a breast cancer resistance protein (BCRP) inhibitor. Co-administration of HOVILPRI with a BCRP substrate may increase the plasma concentrations of the BCRP substrate, which may increase the risk of adverse reactions.
Concomitant use of acid-reducing agents may elevate gastric pH and decrease the systemic bioavailability of HOVILPRI, which may reduce its effectiveness or cause drug resistance to HOVILPRI. Avoid concomitant use with esomeprazole or rabeprazole. Avoid concomitant use with omeprazole or lansoprazole at daily doses above 20 mg, or with pantoprazole at daily doses above 40 mg. Take HOVILPRI at least 2 hours before or 12 hours after H2-receptor antagonists. Take HOVILPRI at least 2 hours before or 2 hours after antacids.
Please see full Prescribing Information athttps://www.hovilprihcp.com/pdf/prescribing-information.pdf.
About Asahi Kasei Therapeutics
Asahi Kasei Therapeutics is the global specialty pharmaceutical business of Tokyo-based Asahi Kasei. We are identifying, developing and commercializing innovative medicines for diseases with significant unmet medical needs. Drawing upon our strong heritage of scientific innovation, we are expanding therapeutic options and helping to positively impact health in immunology, nephrology, transplantation, and infectious diseases. For more information, visit: https://www.aktx.com.
About Asahi Kasei
Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world’s challenges across its three business sectors: Healthcare, Homes, and Material. For more information, visit https://www.asahi-kasei.com/.
Asahi Kasei positions Pharmaceuticals as a First Priority business in its medium-term management plan, emphasizing value creation by expanding its research and development activities globally to deliver innovative therapeutic options worldwide.
References:
1. HOVILPRI (pritelivir) tablets. Prescribing information. Asahi Kasei Therapeutics, Inc.; 2026.
2. Birkmann A et al. J Med Chem. 2022;65(20):13614-13628. doi:10.1021/acs.jmedchem.2c00668
3. Birkmann A, Saunders R. Antiviral Res. 2025;237:106152. doi:10.1016/j.antiviral.2025.106152
4. Papanicolaou GA et al. Oral late-breaker presented at: Tandem Meetings; February 4-7, 2026; Salt Lake City, Utah.
5. AiCuris Anti-infective Cures AG. FDA Breakthrough Therapy designation and Priority Review correspondence. Data on file.
6. AiCuris Anti-infective Cures AG. Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026. Published April 16, 2026.
7. Shafat T et al. Clin Microbiol Infect. 2025;31(5):761-772. doi:10.1016/j.cmi.2025.01.033
8. Hammond SP et al. Open Forum Infect Dis. 2024;11(3):ofae046. doi:10.1093/ofid/ofae046
9. Sallée L, Boutolleau D. Rev Med Virol. 2024;34(5):e2574. doi:10.1002/rmv.2574
10. Chemaly RF et al. Clin Infect Dis. 2025;81(3):593-601. doi:10.1093/cid/ciae638
11. Harfouche M et al. Sex Transm Infect. 2025;101(4):214-222. doi:10.1136/sextrans-2024-056307
12. Workowski KA et al. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1
US-PRI-2600128
Headquarters of Asahi Kasei Corporation in Tokyo, Japan
President Donald Trump opened another chapter in his effort to fire Federal Reserve Governor Lisa Cook Friday by establishing a “committee of inquiry” to investigate allegations that she made false statements in mortgage applications.
The inquiry will include a hearing at the White House on Nov. 5 and Cook “shall” attend to answer questions from the committee, Trump said in a written memo.
Vice President JD Vance cast doubt on Friday about whether the Pentagon will livestream the execution of the Fort Hood shooter in December, telling reporters he wouldn’t watch it. “I don’t know that that’s actually going to happen,” Vance told reporters. He and Trump have both sought to highlight the shooter’s 2009 attack at Fort Hood where he killed 13 people.
Trump said he has struck a deal to obtain over a million tons of diesel from Russia, a stunning reversal of years of U.S. pressure on Moscow as fuel prices remain high ahead of the U.S. midterm elections. Ukrainian President Volodymyr Zelenskyy called it, “a weak decision by strong partners,” and suggested negotiations between the U.S. and Ukraine on how to end the war were “being used as a smoke screen.”
Also, a federal immigration officer shot a Dominican man in the neck as he drove in a car with a 5-year-old boy Thursday afternoon, officials said.
An irate New York Mayor Zohran Mamdani called the shooting an outrage, and spent two hours Thursday night pressing President Donald Trump and Homeland Security Secretary Markwayne Mullin to release the wounded man, and urging them to stop immigration enforcement operations in the city.
Here's the latest:
National Guard officials in D.C. have directed troops to avoid standing near drop boxes or polling locations after a photo circulated on social media of several guardsmen surrounding a ballot drop box near a Metro station.
The city elections division said it had reached out to the Guard asking they impose limitations on the placement of National Guard service members near drop boxes and other voting locations in the D.C.
More than 2,900 Guard members remain in the city, part of a task force started in August 2025 by Trump to curb crime. D.C. Council Chair Phil Mendelson said his office had received multiple calls about troops near ballot drop boxes.
“Soldiers standing by our ballot boxes is unnecessary and is fundamentally wrong if we want to encourage voting,” he said.
Fellow Council member Brooke Pinto is planning a public hearing on the deployment next month.
The president is in New York for an event supporting Bruce Blakeman, a Republican ally who is trying to unseat Democratic incumbent Gov. Kathy Hochul.
Trump arrived on Air Force One and is headed to a rally where Blakeman has been speaking to supporters.
Blakeman has embraced Trump even as Republicans look to capture centrists in a state where Democrats outnumber Republicans by more than 2-to-1.
The Nassau County executive has played up fears about immigrant criminals and depicted the state as dangerous and unaffordable.
The Democratic Congressional Campaign Committee says an infusion of $17 million by Oct. 22 could help the party win at least six additional Republican-held seats, according to a memo from the group’s finance director obtained by The Associated Press.
The committee is eyeing another roughly dozen districts in addition to the 17 where it has focused its campaign money.
A U.S. Supreme Court decision in June held that political parties and their affiliated groups could contribute directly to candidate’s campaigns, reversing the previous ban. Democratic House campaign leaders are arguing that the extra money could lift the handful of Democratic House candidates, in part because the money going directly to candidates would go further in light of lower rates charged to campaigns. Super PACs are charged higher rates.
The districts include one in south Florida where three-term Republican Rep. Maria Elvira Salazar has criticized President Donald Trump’s immigration enforcement as “going too far.”
Trump said his arrangement with his Russian counterpart for diesel exports — coming weeks before the midterm elections — is “a big deal.”
“That is massive amounts of oil coming into our country,” he said as he left the White House heading to Syracuse, New York, for rally.
“I want to thank President Putin. To be honest with you, we have massive amounts of oil coming into our country, and it’s diesel, which is what we want. So, thank you.”
Trump did not answer shouted questions about criticism from Zelenskyy, who called it a “weak decision” and said the deal would give Putin more money “to inflict suffering on us” in the ongoing war.
Sen. Mark Warner, the top Democrat on the Intelligence Committee, condemned Hegseth’s plan, saying there’s a reason why “almost no countries in the world engage in this barbaric practice.”
“Public executions are the hallmark of authoritarian regimes like Iran and North Korea, not the United States of America,” Warner said.
“Beyond the profound moral concerns, a public execution could hand terrorist organizations a propaganda victory,” he said, and put U.S. service members and others overseas at risk.
Republican Sen. John Curtis of Utah pointed to Rome’s bloody spectacles and said a “civilization erodes when it cultivates an appetite for executions as a form of entertainment.”
“Secretary Hegseth’s plan to livestream the Fort Hood execution risks feeding that appetite,” Curtis said. “I urge him to reconsider.”
GOP Sen. Lisa Murkowski of Alaska said how the U.S. carries out justice matters.
“I would expect this from terrorists and dictators, but not here in America,” she said. “I urge the Pentagon to reverse this gruesome decision.”
Trump says he approves of Hasan’s execution by firing squad.
The Army psychiatrist convicted of killing 13 people in 2009 at Fort Hood in Texas is scheduled to be executed by firing squad on Dec. 3.
The Pentagon had announced on Thursday that it plans to livestream the execution. It would be the first U.S. military execution since 1961.
“He will be killed. He will be, through firing squad,” Trump told reporters before flying to Syracuse, New York, for a political event. “I really don’t care how he goes, as long as he goes. And I think the death penalty is a very worthy way of going for him.”
Trump did not appear to answer when asked whether it was appropriate to livestream the event or whether he was going to watch the execution.
Zelenskyy called the deal Trump struck to obtain diesel from Russia, “a weak decision, unfortunately, a weak decision by strong partners,” according to a statement released by the Ukrainian Embassy in Washington.
Trump’s announced the deal as his envoy Steve Witkoff and son-in-law Jared Kushner were meeting with Ukrainian officials to discuss a proposal to try to end the Russia-Ukraine war.
“I believe our team is simply being used as a smokescreen. And that is certainly not fair. It is certainly not how partners should treat each other,” Zelenskyy said.
▶ Read more
The president appeared with the former heavyweight champion as he left the White House to fly to his rally on Friday night in Syracuse, New York.
“This is Iron Mike Tyson,” Trump told reporters gathered on the White House lawn for his departure, before joking, “I won’t be fighting him today.”
Trump noted that he and Tyson have “been friends for a long time” and the crowd will “be happy to see Mike.”
Tyson was convicted of rape in 1992, and served three years in prison.
The event in Los Angeles was meant to bring attention to the candidate’s promise to lower California’s highest-in-the-nation gas prices to $3 a gallon. The average rate in the state stood at $6.33 per gallon Friday, according to AAA.
“This is a preview of what you get when I’m governor,” he told a driver in a video posted to his X page.
Hilton, a former Fox News host who’s running against Democrat Xavier Becerra, has blamed Democratic leadership for the state’s notoriously high cost of living.
He’s making a final push to appeal to voters with mail ballots being sent out ahead of the Nov. 3 deadline to vote.
The United Democracy Project, a super PAC affiliated with the American Israel Public Affairs Committee, or AIPAC, has begun spending against Michigan’s Democratic Senate candidate Abdul El-Sayed. The spending was revealed in a filing late Friday, and is only $94,000 to start.
The group spent close to $30 million against El-Sayed — a vocal critic of Israel — in his Democratic primary against Rep. Haley Stevens. Until Friday, the group had stayed out of the general election race. During a Senate debate Thursday, El-Sayed’s opponent, Mike Rogers, signaled he would accept AIPAC’s support when asked directly about it.
A spokesperson for AIPAC did not immediately respond to a request for comment.
The president said conservative commentator Katie Zacharia, a communications adviser for Trump’s media company, will replace Karoline Leavitt as the chief spokesperson for the White House.
Trump announced the hire in a social media post on Friday, describing Zacharia as “a loyal and brilliant supporter, right from the beginning.”
Zacharia briefly worked as a spokesperson for the Department of Homeland Security earlier this year and has been a commentator for Fox News and Newsmax. Trump said she was previously involved in his campaigns and helped in key swing states.
A request for comment left with Zacharia was not immediately answered. Her LinkedIn says she has a law degree from Pepperdine University.
The president has now formally confirmed that Hurricane Isaias means he won’t be attending Saturday night’s Alabama-Georgia football game.
He wrote on his social media site on Friday that “based on the fact that a huge Hurricane/Storm is coming, it is important to have our wonderful First Responders, Law Enforcement, and others, focused on that Storm, and in no way be thinking about the safety, or presence, of the President of the United States, ME!”
“Therefore, I will miss that potentially unbelievable Game, Alabama vs. Georgia,” Trump continued. “But, hopefully, the Game will go on despite the weather!”
He also promised, without providing details, “I will be visiting both of those Teams at a later date.”
The president will no longer be attending Saturday’s football game between the University of Alabama and the University of Georgia, according to a White House official speaking on condition of anonymity to discuss internal planning.
Trump had been planning to travel to Tuscaloosa for the rivalry clash after a rally planned in Tennessee on Saturday. Asked about the impact of the storm on Wednesday said “I gotta go to the game” but said his plans might change based on the weather.
Trump had said he did not want to divert resources from the emergency response.
President Donald Trump said that he has struck a deal to obtain diesel from Russia, a stunning reversal of years of U.S. pressure on Moscow over its war with Ukraine and an attempt to address high fuel prices ahead of the U.S. midterm elections.
Trump said on social media on Friday that he struck the deal with Russian President Vladimir Putin in a phone call in which he was expected to discuss a suspected case of plague in Russia. Instead, Trump announced that Russia will immediately supply more than 300,000 tons of diesel, followed by an additional 500,000 tons in November and 1 million tons “immediately thereafter.” Russia will deliver another 3 million tons “within a short period of time” after that, he wrote.
Trump’s shocking announcement comes after he signed a sweeping Russia sanctions law last month that aimed at clamping down on Russia’s energy economy, among other areas, that fuel its war against Ukraine.
▶ Read more
Katie Zacharia has been offered the job as press secretary, according to a White House official speaking on condition of anonymity to discuss internal hiring.
It was not immediately clear whether she has accepted. A message left with Zacharia was not immediately answered on Friday. The post has been open since Karoline Leavitt left in August.
Zacharia is a senior communications adviser for Trump Media & Technology, the company behind the Truth Social platform. She briefly worked as a spokesperson for the Department of Homeland Security this year, and according to her LinkedIn profile has been a commentator for Fox News and Newsmax.
Her LinkedIn profile says she has bachelor’s and law degrees from Pepperdine University.
Earlier Friday morning, the head of the U.S. Conference of Catholic Bishops condemned the U.S. government’s decision to livestream the execution of Nidal Hasan by firing squad.
Vice President Vance is a convert to the Catholic Church, which has long opposed capital punishment.
“It is with shock and great sorrow that I have learned of the Department of War’s decision to publicly livestream the execution,” Archbishop Paul S. Coakley, president of the conference, said in a statement. He added that the decision was “a barbaric promotion of a culture of death and must be reconsidered.”
New York Rep. Alexandria Ocasio-Cortez will travel to Michigan next week to campaign with Democratic Senate nominee Abdul El-Sayed, further throwing her substantial platform behind a fellow progressive in one of the nation’s most competitive Senate races.
Ocasio-Cortez, one of the most prominent figures in the progressive movement, said at a New York City fundraiser last week that “if Abdul can win in Michigan, anybody can win anywhere.”
The two will campaign Oct. 15 in Michigan’s Upper Peninsula, a heavily Republican region that will test the appeal of their progressive politics. They will then travel to southeast Michigan for campaign events Oct. 16.
“Abdul has built a winning coalition with an agenda to bring down costs for Michigan families and I could not be more excited to join him for the final stretch of this race,” Ocasio-Cortez said in a statement.
“These are accusations. You don’t take messages that people allegedly had between one person or another — or one person’s story — and say, ‘Oh, because of that, Kimberly Guilfoyle is guilty,’ the vice president told reporters.
The Wall Street Journal has reported that Guilfoyle, the U.S. ambassador to Greece, asked a donor and supporter of U.S. President Donald Trump to pay a $100,000 credit card bill just before her confirmation hearing and that she promising him access to administration officials if he did.
Vance suggested it was too early to reach conclusions about Guilfoyle and the allegations.
“Let’s actually see what the facts are. Let’s see what the truth is,” he said. “And, obviously, if there was something bad that happened, then people have to suffer consequences.”
Vice President JD Vance cast doubt on Friday whether the Pentagon will livestream the execution of Fort Hood shooter Nidal Malik Hasan in December but told reporters that if it is livestreamed, “I’m not going to be watching it.”
The Republican vice president said, “I don’t know that that’s actually going to happen,” when asked about the plans that the Pentagon confirmed on Thursday. But Vance then tried to set aside the controversy over the shocking plans for a public execution and said Hasan’s crimes should not be forgotten.
“So whatever the controversy is about the method of the execution, I hope that people don’t forget that this is a guy who brutally murdered a lot of innocent people,” the Republican said.
“Now, that said, I mean, look, if it’s ultimately livestreamed, I’m not going to be watching it,” he said.
▶ Read more
Trump says his administration “resurrected” Christopher Columbus and other figures from American history whose statues and legacies were being threatened by what he called the “radical left.”
In a meandering address at a Columbus Day celebration at the White House, Trump said: “They want to tear down the history and heritage that makes us who we are, not only Columbus.”
He said George Washington and Thomas Jefferson had been targets too. “We had a time when they wanted to rip down the statue of Abraham Lincoln,” because “they thought he was a racist. He’s the one that freed the country,” Trump said.
There have been laws on the books for years to punish people for defacing monuments and statues. Trump signed executive orders in 2020 that ordered monuments to be rebuilt and pushed for tougher punishments for people who defaced them.
FILE - Federal Reserve Board of Governors member Lisa Cook leaves the Supreme Court in Washington, Jan. 21, 2026. (AP Photo/Mark Schiefelbein, File)
President Donald Trump arrives to speak at the U.S. Institute of Peace, Thursday, Oct. 8, 2026, in Washington. (AP Photo/Julia Demaree Nikhinson)
New York City Mayor Zohran Mamdani talks during a news conference near the scene of a shooting on Thursday, Oct. 8, 2026, in New York. (AP Photo/Seth Wenig)
